

# Newcomer in ECLS<sup>1)</sup> market: Inspira ART™ system for early extracorporeal respiratory support (ECRS) treatment.

## The ART™ System (Augmented Respiration Technology)



Disposable Respiratory Support Unit



Control Unit



Dual Lumen Cannula



- Founded in 2018 in Israel.
- First ART™ prototype in March 2020.
- About 20 FTEs, with fast expansion plan after completing a successful IPO on the Nasdaq in July 2021 (\$16 million raised).
- Top ranked healthcare start-up in Israel<sup>2)</sup>.



## Early ECRS Treatment

- Main goal: Minimize the need for and consequences of aggressive mechanical ventilation.
- Targeted use case: Between supplementary oxygen treatments (xPAP) and mechanical ventilation, as well as in conjunction with mechanical ventilation.
- Technology: Proprietary hemo-protective low flow (1-1.5 l/min) incl. oxygenation and removal of CO<sub>2</sub>.



### Strengths

- New use case: away from last resort ECLS treatment towards early stage support.
- Affordable treatment (disposable unit estimated target price ~\$1'250 per patient).
- Does not require an ICU. It can be used in general wards and ambulatory settings.
- Easy-to-use & easy to apply, limiting opportunities for human error:
  - Plug-and-play cartridge with preassembled consumables.
  - Ready-for-use system via self-priming / automatic flushing.
  - Less invasive system with low flow approach.



### Weaknesses

- Has not been tested or used in humans. To date, only animal studies performed.
- Not approved by the FDA, nor possesses CE mark.
- Target is to deploy the first systems by the end of 2022.